From October 28 to 30, 2025, the CPHI Worldwide 2025 will be held at Messe Frankfurt in Germany. For conference attendees, Henlius will showcase its robust biologic pipeline and cutting-edge R&D platform including its proprietary recombinant human hyaluronidase, at booth #3.1A92.
As the world's largest and most influential professional exhibition in the pharmaceutical industry, CPHI Worldwide has successfully completed 36 editions. The event brings together leading pharmaceutical companies, investors, and strategic partners from around the globe, serving as a key platform for technology exchange, knowledge sharing, and industry collaboration. Each year, stakeholders convene to explore emerging trends and market opportunities, driving innovation and progress across the sector.
The United States is the world’s largest biologics market, yet high prices of originator products have long posed a significant burden on patients.1 Biosimilars have greatly improved treatment accessibility and affordability.2 In recent years, the FDA has advanced the modernization of approval pathways, including discussing the necessity of Phase 3 efficacy trials in biosimilar development and exploring the possibility of reducing or waiving certain traditional study requirements when analytical and clinical comparability is sufficient. These efforts aim to expedite approvals and bring benefits to patients sooner.
During the exhibition, the company will showcase a range of biologics and innovative technology platforms at booth 3.1A92. Among the highlights is Henozye®, the company’s proprietary next-generation recombinant human hyaluronidase. Henozye® features exceptional stability and compatibility, making it adaptable for multiple complex scenarios and various molecules—including monoclonal antibodies, polyclonal antibodies, and ADCs—where large-volume subcutaneous administration is required. It maintains robust performance across diverse buffer systems and stable in very wide pH range, significantly broadening its application scenarios and enhancing the success rate of co-formulation development, thereby extending product lifecycle. With the multi-billion dollar global market potential for subcutaneous administration and growing patient demand for more convenient therapies, Henozye® stands out as a key technology solution with independent IP. It positions Henlius to collaborate with industry partners in improving patient adherence and overcoming formulation challenges, thereby unlocking significant clinical value and promising prospects for collaboration.
In addition, the company will also showcase its 9 launched products and a rich pipeline, including HANSIZHUANG (serplulimab, trade name: Hetronifly in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, HANQUYOU (trastuzumab, trade name: HERCESSI in the U.S., Zercepac in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANLIKANG (rituximab), the first China-developed biosimilar, denosumab BILDYOS and BILPREVDA, as well as core underdevelopment innovative products such as HLX43 (PD-L1 ADC), HLX22 (novel enpitope anti-HER2 mAb), and HLX07 (anti-EGFR mAb).
As a global biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 9 products have been approved for marketing worldwide, and 4 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Leveraging the advanced technologies and extensive resources, the company continued to reinforce its integrated biopharmaceutical platform including R&D, clinical trials, manufacturing, quality management, regulatory affairs, and commercialization. Through strategic collaborations with globally recognized partners including Accord, Abbott, Dr. Reddy’s, Organon, Sandoz, and Intas, the company is also accelerating the regulatory registration of its product portfolio overseas.
We remain committed to addressing unmet clinical needs, with a deep focus on disease areas including oncology and autoimmune diseases, while continuously expanding international collaborations. We warmly invite you to visit us at booth 3.1A92, Messe Frankfurt, to explore the future of biopharmaceutical innovation together.